Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 2 | unknown | — |
The patient took second dose of Vivotif three days after the first dose; Case reference number US-BN-2025-000906 is a spontaneous case initially received from pharmacist via agency (reference number: USBAV25-1018) on 05-May-2025 and concerns a female patient of unspecified age. The patient's medical history and concomitant medication details were not provided. On 01-May-2025 (to be confirmed), the patient took first dose of Vivotif (batch number: unknown) at unknown dose, route or site of administration, for unknown indication. On 04-May-2025 (to be confirmed), three days after the first dose, the patient took second dose of Vivotif (batch number: unknown) at unknown dose, route or site of administration, for unknown indication (explicitly coded as 'inappropriate schedule of vaccine administered '). At the time of initial report, it was unknown if the patient experienced any of adverse events due to Vivotif. No further information was provided.; Reporter's Comments: A female patient of unspecified age took the second dose of Vivotif three days after the first dose for unknown indication, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any of adverse events due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A female patient of unspecified age took the second dose of Vivotif three days after the first dose for unknown indication, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any of adverse events due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: NONE